Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

345 ARTÍCULOS , VIENDO DEL 331 AL 345

Biomarker evidence for uncoupling of amyloid build-up and toxicity in Alzheimer's disease

Zetterberg H, Blennow K.

Alzheimers Dement. 2013 Jul;9(4):459-62. doi: 10.1016/j.jalz.2012.07.002. Epub 2012 Nov 14.

Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease?

Brown BM, Peiffer JJ, Martins RN.

Mol Psychiatry. 2013 Aug;18(8):864-74. doi: 10.1038/mp.2012.162. Epub 2012 Nov 20.

Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?

Mullane K, Williams M.

Biochem Pharmacol. 2013 Feb 1;85(3):289-305. doi: 10.1016/j.bcp.2012.11.014. Epub 2012 Nov 23.

Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease

León R, Garcia AG, Marco-Contelles J.

Med Res Rev. 2013 Jan;33(1):139-89. doi: 10.1002/med.20248. Epub 2011 Jul 26.

HtrA protease family as therapeutic targets

Skorko-Glonek J, Zurawa-Janicka D, Koper T, Jarzab M, Figaj D, Glaza P, Lipinska B.

Curr Pharm Des. 2013;19(6):977-1009. doi: 10.2174/1381612811319060003.

Mitochondria as a pharmacological target: magnum overview

Olszewska A, Szewczyk A.

IUBMB Life. 2013 Mar;65(3):273-81. doi: 10.1002/iub.1147.

Early Alzheimer's and Parkinson's disease pathology in urban children: Friend versus Foe responses--it is time to face the evidence

Calderón-Garcidueñas L, Franco-Lira M, Mora-Tiscareño A, Medina-Cortina H, Torres-Jardón R, Kavanaugh M.

Biomed Res Int. 2013;2013:161687. doi: 10.1155/2013/161687. Epub 2013 Feb 7.

Ghrelin as a neuroprotective and palliative agent in Alzheimer's and Parkinson's disease

Dos Santos VV, Rodrigues AL, De Lima TC, de Barioglio SR, Raisman-Vozari R, Prediger RD.

Curr Pharm Des. 2013;19(38):6773-90. doi: 10.2174/13816128113199990411.

Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer's disease: implications for synaptic dysfunction and neuronal damage

Reddy PH.

Biochim Biophys Acta. 2013 Dec;1832(12):1913-21. doi: 10.1016/j.bbadis.2013.06.012. Epub 2013 Jun 28.

Molecular biomarkers of neurodegeneration

Höglund K, Salter H.

Expert Rev Mol Diagn. 2013 Nov;13(8):845-61. doi: 10.1586/14737159.2013.850033.

Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration

Duarte AI, Candeias E, Correia SC, Santos RX, Carvalho C, Cardoso S, Plácido A, Santos MS, Oliveira CR, Moreira PI.

Biochim Biophys Acta. 2013 Apr;1832(4):527-41. doi: 10.1016/j.bbadis.2013.01.008. Epub 2013 Jan 11.

Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases

Bharadwaj PR, Bates KA, Porter T, Teimouri E, Perry G, Steele JW, Gandy S, Groth D, Martins RN, Verdile G.

Transl Psychiatry. 2013 Dec 3;3(12):e332. doi: 10.1038/tp.2013.97.

Cervical dystonia in an Alzheimer's disease patient treated with donepezil

Yagi Y, Watanabe Y, Yokote H, Amino T, Kamata T.

Acta Neurol Belg. 2013 Sep;113(3):363-4. doi: 10.1007/s13760-012-0143-9. Epub 2012 Oct 11.

The unravelling of metabolic dysfunctions linked to metal-associated diseases by blue native polyacrylamide gel electrophoresis

Han S, Auger C, Castonguay Z, Appanna VP, Thomas SC, Appanna VD.

Anal Bioanal Chem. 2013 Feb;405(6):1821-31. doi: 10.1007/s00216-012-6413-9. Epub 2012 Sep 22.

Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand

Kulkantrakorn K, Tanyakitpisal P, Towanabut S, Dejthevaporn C, Rangseekajee P, Pongpakdee S, Laptikultham S, Rodprasert K, Setthawatcharawanich S, Thinkhamrop B.

Psychogeriatrics. 2013 Mar;13(1):1-8. doi: 10.1111/j.1479-8301.2012.00403.x. Epub 2012 Feb 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias